Latest News for: cd73

Edit

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

PR Newswire 25 Feb 2026
ATG-037, Antengene's orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 monoclonal antibodies ... facilitate complete CD73 inhibition at the cellular level.
  • 1
×